A5079118086- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Neuroinflammation and Neurodegeneration Mechanisms
- Systemic Lupus Erythematosus Research
- Neurogenesis and neuroplasticity mechanisms
- Peripheral Neuropathies and Disorders
- Cytokine Signaling Pathways and Interactions
- Reproductive System and Pregnancy
- Acute Lymphoblastic Leukemia research
- RNA regulation and disease
- Psoriasis: Treatment and Pathogenesis
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Viral Infections and Immunology Research
- Family Support in Illness
- Vitamin D Research Studies
- Mycobacterium research and diagnosis
- Pregnancy and Medication Impact
- SARS-CoV-2 and COVID-19 Research
- Prion Diseases and Protein Misfolding
- Sphingolipid Metabolism and Signaling
- Child Abuse and Trauma
- T-cell and B-cell Immunology
- Inflammatory Bowel Disease
- Vitamin C and Antioxidants Research
- Systemic Sclerosis and Related Diseases
Haukeland University Hospital
2015-2025
University of Bergen
2015-2025
St Olav's University Hospital
2022
Telemark Hospital
2021
Vestre Viken Hospital Trust
2021
Stavanger University Hospital
2021
Norwegian University of Science and Technology
2021
University of Basel
2017
University Hospital of North Norway
2016
Oslo University Hospital
2012
Background and objective: We explored which clinical biochemical variables predict conversion from clinically isolated syndrome (CIS) to definite multiple sclerosis (CDMS) in a large international cohort. Methods: Thirty-three centres provided serum samples 1047 CIS cases with at least two years’ follow-up. Age, sex, presentation, T2-hyperintense lesions, cerebrospinal fluid (CSF) oligoclonal bands (OCBs), CSF IgG index, cell count, 25-hydroxyvitamin D3 (25-OH-D), cotinine titres against...
To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS).A cohort of 85 patients with RRMS were followed for 2 years (6 months without disease-modifying treatment 18 interferon-beta 1a [IFNB-1a]). Expanded Disability Status Scale was scored at baseline every 6 thereafter. MRI performed monthly 9 then 12 24. Serum samples collected 3, 6, 12, We analyzed the levels NF-L using a single-molecule array...
To investigate whether ω-3 fatty acids reduce magnetic resonance imaging (MRI) and clinical disease activity in patients with multiple sclerosis, both as monotherapy combination interferon beta-1a treatment.Multicenter, randomized, double-blind, placebo-controlled trial conducted from 2004 to 2008.Thirteen public neurology departments Norway.Patients aged 18 55 years active relapsing-remitting a disability score equivalent 5.0 or less on the Kurtzke Expanded Disability Status Scale....
<h3>Objective:</h3> Studies based on deseasonalized vitamin D levels suggest that may influence the disease activity in multiple sclerosis (MS), and high doses are suggested as add-on treatment to interferon-β (IFN-β). Seasonal fluctuation of varies between individuals, thus relationship should preferentially be studied by repeated simultaneous MRI measurements from each patient. <h3>Methods:</h3> This was a cohort study comprising 88 patients with relapsing-remitting MS who were followed...
Vitamin D is emerging as a probably important environmental risk factor in multiple sclerosis, affecting both susceptibility and disease progression. It not known to what extent this effect due modulation of peripheral lymphocyte function, or intrathecal effects vitamin D. We investigated the dietary D3 content on de/remyelination cuprizone model, which well established toxic model demyelination, with no associated infiltration. The mice received diets either deficient (<50 IU/kg),...
Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development protective immunity paramount importance to fight COVID-19 pandemic. Objective To characterise humoral after mRNA-COVID-19 vaccination people with multiple sclerosis (pwMS). Methods All pwMS in Norway fully vaccinated against SARS-CoV-2 were invited a national screening study. Humoral was assessed by measuring anti-SARS-CoV-2 SPIKE RBD IgG response 3–12 weeks...
Previous reports indicate an association between Epstein-Barr virus (EBV) antibody levels and multiple sclerosis (MS) disease activity, but the results have been conflicting.The objective of this paper is to study if EBV reflect MRI activity in MS examine potential for as biomarkers treatment response.A total 87 patients were followed two years prior during interferon beta (IFNB) treatment, with examinations serum measurement IgM IgG antibodies viral capsid antigen (VCA), nuclear 1 (EBNA-1)...
Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly cohorts de novo patients early escalation.To investigate the treatment with rituximab an MS-cohort predominantly or escalation.We retrieved from Norwegian MS-registry biobank for all MS-patients treated at Haukeland University Hospital, Bergen, Norway, during a four year period.In 365 (320 relapsing-remitting MS (RRMS), 23 secondary...
Abstract Objective To study the age at onset of relapsing–remitting multiple sclerosis (RRMS) during past century. Methods This is a population-based cohort persons diagnosed with RRMS in Hordaland, Møre, and Romsdal counties, Western Norway, from 1920 to 2022. Individual patient data were available assessed previously conducted prevalence incidence studies addition hospital records up until October 31, Participants categorized according period analyzed for temporal trends onset, time...
In multiple sclerosis (MS), the correlation between lesion load on conventional magnetic resonance imaging (MRI) and clinical disability is weak. This clinico-radiological paradox might partly be due to low sensitivity of MRI detect gray matter demyelination. Magnetization transfer ratio (MTR) has previously been shown white demyelination in mice. this study, we investigated whether MTR can cuprizone exposed A total 54 female C57BL/6 mice were split into one control group () eight groups...
Vitamin D supplementation is increasingly recommended to patients with multiple sclerosis (MS). To study the effect of high-dose vitamin on remyelination, female C57Bl/6 mice were demyelinated dietary 0.2% cuprizone for 7 weeks. The received intraperitoneal injections 1.25-dihydroxyvitamin D3 (calcitriol) or placebo (vehicle) twice a week, from week 6, throughout 9. Mice that calcitriol had initially increased demyelination (p = 0.021), astrocytosis 0.043), and microglia activation. However,...
Background: Vitamin A has immunomodulatory properties and may regulate the transcription of genes involved in remyelination. Objective: To investigate association between retinol disease activity multiple sclerosis (MS). Methods: Cohort study 88 relapsing–remitting MS patients, originally included a randomised placebo-controlled trial omega-3 fatty acids (the OFAMS study), followed prospectively for 24 months with repeated assessments serum-retinol magnetic resonance imaging (MRI). All...
The cuprizone model is a of de- and remyelination secondary to oligodendrocyte death, likely be mediated by an inhibition mitochondrial function. aim this study was characterize histopathological changes associated with de/remyelination in grey white matter at different disease stages C57Bl/6 mice after per oral administration cuprizone. Oligodendrocyte loss, astrocytosis complement activation detected areas demyelination. Demyelination, occurred earlier the cerebral cortex than corpus...
Abstract Two pathophysiological different experimental models for multiple sclerosis were analyzed in parallel using quantitative proteomics attempts to discover protein alterations applicable as diagnostic-, prognostic-, or treatment targets human disease. The cuprizone model reflects de- and remyelination sclerosis, the autoimmune encephalomyelitis (EAE, MOG1-125) immune-mediated events. frontal cortex, peripheral severely inflicted areas CNS, was dissected analyzed. cortex had previously...
<h3>Objective</h3> To assess the occurrence of perinatal depression and anxiety in women before after diagnosis multiple sclerosis (MS). <h3>Methods</h3> A total 114,629 pregnant were included Norwegian Mother, Father Child Cohort study (1999–2008). We assessed by questionnaires during pregnancy. Women with MS identified from national health registries hospital records grouped into (1) diagnosed pregnancy (n = 140) or (2) symptom onset 98) (3) 308). Thirty-five postpartum period. The...
Cladribine tablets are contraindicated during pregnancy; therefore, safety data on pregnancies exposed to this treatment limited. CLEAR collects and describes pregnancy outcomes in understudied population. To describe the main features of study design, including sources methodological approach, provide a status update. is non-interventional, multi-database, comparative cohort study. Four cohorts included: women with multiple sclerosis (MS) cladribine (maternal exposed); MS unexposed any...
Magnetization transfer ratio (MTR) is a magnetic resonance imaging (MRI) method which may detect demyelination not detected by conventional MRI in the central nervous system of patients with multiple sclerosis (MS). A decrease MTR value has previously been shown to correlate myelin loss mouse cuprizone model for demyelination. In this study, we investigated sensitivity oligodendrocyte (MOG) 1-125 induced experimental autoimmune encephalomyelitis (EAE) model. total 24 female c57Bl/6 mice were...
Background and purpose Our objective was to study the association between serum levels of anti Epstein–Barr virus nuclear antigen 1 ( EBNA ‐1) antibody 25‐hydroxyvitamin D (25( OH )D) in a prospective cohort patients with relapsing−remitting multiple sclerosis. Method The comprised 90 sclerosis, all participants randomized clinical trial ω‐3 fatty acids (the OFAMS study). Repeated, paired measurements 25( )D ‐1 immunoglobulin G (IgG) were obtained at baseline every 6 months for 24 months....
Fingolimod (FTY720) is approved for treatment of relapsing–remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but vivo animal not detected any positive effect on cerebral remyelination. The discrepant findings could be a result different mechanisms underlying and cuprizone model de- was used to evaluate whether had an impact vivo. We did remyelination, number mature oligodendrocytes, microglia or astrocytes when fed after exposure.
The underlying mechanisms for neurodegeneration in multiple sclerosis are complex and incompletely understood. Multivariate multimodal investigations integrating demographic, clinical, multi-omics, neuroimaging data provide opportunities nuanced analyses, aimed to define disease progression markers. We used from a 12-year longitudinal cohort of 88 people with sclerosis, test the predictive value MRI, clinical examinations, self-reports on quality life, demographics, general health-related...
Background: Head-to-head comparisons of high-efficacy therapies for relapsing–remitting multiple sclerosis (RRMS) are lacking. We conducted a target trial emulation to compare the long-term effectiveness rituximab and cladribine. Methods: estimated effect initiating treatment with versus cladribine using observational data from Norwegian MS Registry Biobank at two university hospitals different strategies. Cumulative incidence risk differences (RDs) were weighted Kaplan-Meier estimators,...
The level of interleukin‐10 (IL‐10) expression is related to polymorphisms ‐1082 (G/A), ‐819 (T/C) and ‐592 (A/C) in the promoter region IL‐10 gene, which constitute three haplotypes, GCC, ATA, ACC. ATA (a non‐GCC) haplotype, associated with low expression, has been shown improve interferon (IFN) treatment response hepatitis C. We analysed distribution haplotype combinations determine whether they could influence initial IFN 63 patients relapsing‐remitting multiple sclerosis (MS). were...